Cryoport (CYRX) Stock Overview
Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CYRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cryoport, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.69 |
| 52 Week High | US$15.85 |
| 52 Week Low | US$5.31 |
| Beta | 1.75 |
| 1 Month Change | 51.59% |
| 3 Month Change | 84.81% |
| 1 Year Change | 190.56% |
| 3 Year Change | -20.52% |
| 5 Year Change | -73.95% |
| Change since IPO | -85.86% |
Recent News & Updates
Narrative Update • May 29
CYRX: Elevated Expectations For Service Group Margins Will Challenge Execution
Analysts have lifted their price targets on Cryoport, prompting an updated fair value estimate from $9.51 to $11.00, citing stronger revenue visibility, improved margin expectations through 2028, and a broad base of commercial and clinical customers as key supports for the stock. Analyst Commentary Recent Street research has leaned constructive on Cryoport, with several firms lifting price targets and highlighting the company’s revenue visibility, margin profile through 2028, and breadth of commercial and clinical relationships.
Narrative Update • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.Recent updates
Narrative Update • May 29
CYRX: Elevated Expectations For Service Group Margins Will Challenge Execution
Analysts have lifted their price targets on Cryoport, prompting an updated fair value estimate from $9.51 to $11.00, citing stronger revenue visibility, improved margin expectations through 2028, and a broad base of commercial and clinical customers as key supports for the stock. Analyst Commentary Recent Street research has leaned constructive on Cryoport, with several firms lifting price targets and highlighting the company’s revenue visibility, margin profile through 2028, and breadth of commercial and clinical relationships.Narrative Update • May 03
CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside
Narrative Update on Cryoport Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view. Analyst Commentary Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.Narrative Update • Apr 19
CYRX: Bullish Coverage And New Freezer Launch Will Test Execution Outlook
Analysts have modestly lifted their price target on Cryoport to $9.51, supported by updated assumptions around discount rates, revenue growth, profit margin, and future P/E that align with recently bullish research coverage on the stock. Analyst Commentary Recent research commentary around Cryoport reflects a mix of optimism and caution.Narrative Update • Apr 03
CYRX: Bullish Freezer Launch And Execution Risks Will Shape Future Returns
Narrative Update The analyst price target for Cryoport has edged higher to $9.51 from $9.50, as analysts highlight supportive assumptions around fair value, revenue growth, discount rate, profit margin and future P/E, supported by recent bullish initiation commentary. Analyst Commentary Even with a slightly higher average price target of $9.51, bearish analysts highlight several areas of concern that could limit upside if company execution falls short of expectations.Narrative Update • Mar 20
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have modestly adjusted their price targets on Cryoport, reflecting updated views on revenue growth expectations, slightly lower discount rates, and a small change in projected profit margins and future P/E. Together, these factors fine tune, rather than overhaul, their $ based valuation case.Narrative Update • Mar 04
CYRX: New Cryogenic Freezer Platform Will Support Future Margin Expansion Potential
Analysts have trimmed their price target on Cryoport to $9.50 from $9.50, reflecting slightly adjusted assumptions around discount rate, revenue growth, profit margin and forward P/E, while keeping their view of fair value unchanged. What's in the News Cryoport issued full-year 2026 revenue guidance in a range of $190.0 million to $194.0 million, outlining expectations based on its current business and various external factors, including macroeconomic conditions, supply chains, inflation, government policy, trade restrictions, currency movements and SEC reported risk factors (company guidance).Narrative Update • Feb 18
CYRX: New Cryogenic Freezer Platform Will Support Long Term Margin Prospects
Analysts have made a small trim to their $9.50 price target on Cryoport, reflecting slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping their fair value view broadly intact. What's in the News Cryoport launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply, aiming to provide reliability, safety, and energy efficiency in a compact format suitable for space constrained labs and facilities (Key Developments).Narrative Update • Feb 04
CYRX: Modest Buybacks And Margin Outlook Will Support Measured Long Term Prospects
Analysts have adjusted their Cryoport price target slightly to reflect marginally higher perceived risk and a slightly lower forward P/E assumption, while still anticipating modest improvements in profit margin. What's in the News The company reported no share repurchases from July 1, 2025 to September 30, 2025 under the buyback announced on August 6, 2024, leaving that authorization unused in the period (Key Developments).Narrative Update • Jan 21
CYRX: Share Repurchases And Higher Margin Outlook Will Drive Future Upside
Analysts have nudged their price target on Cryoport slightly lower to US$13.22. This reflects modest tweaks to discount rate assumptions, slightly softer revenue growth expectations, a small uplift in forecast profit margins and a minor adjustment to the future P/E multiple.Narrative Update • Jan 06
CYRX: Higher 2025 Guidance And Buybacks Will Support Measured Long Term Prospects
Analysts have trimmed their price targets on Cryoport to reflect a slightly lower assumed future P/E multiple, while keeping fair value estimates steady. Updated views on discount rates and future revenue contraction narrow but do not materially change the long term margin outlook.Narrative Update • Dec 20
CYRX: Higher Guidance And New Facilities Will Support Measured Long Term Prospects
Analysts have nudged their price target on Cryoport higher by approximately 19 percent, now implying a fair value closer to 9.50 dollars per share. They cite slightly improved long term revenue expectations and modestly better profit margin forecasts, despite a marginally higher discount rate.Narrative Update • Dec 06
CYRX: Improving Gross Margins And $400 Million Cash Will Drive Upside
Analysts have lifted their price target on Cryoport to $15.00 from $10.00, citing improving gross margins, accelerating product revenue growth, and a solid cash position that helps offset prior policy related concerns. Analyst Commentary Bullish analysts view the recent price target increase as evidence that the market is beginning to look past prior policy related uncertainties and refocus on Cryoport's improving fundamentals.Narrative Update • Nov 22
CYRX: Rising Gross Margins and $400 Million Cash Will Support Recovery
The analyst consensus price target for Cryoport has increased by $5. This reflects improving gross margins, stronger product revenue growth, and a more favorable market outlook according to analysts.Narrative Update • Nov 06
CYRX: Improved Gross Margin And Cash Strength Will Drive Rebound
Analysts have raised their price target for Cryoport by $1.11 to $13.22. They cite improved gross margin, stronger product revenue growth, and increased confidence as market conditions stabilize.Narrative Update • Aug 07
Cold Chain Expansion Will Support Cell And Gene Therapies
Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11. What's in the News Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.Analysis Article • Jul 22
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 1.4x Cryoport, Inc. ( NASDAQ:CYRX ) may be sending very bullish signals at...Analysis Article • May 30
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
Key Insights Cryoport will host its Annual General Meeting on 6th of June Salary of US$921.2k is part of CEO Jerry...Analysis Article • Apr 09
Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
New Narrative • Mar 30
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.Analysis Article • Mar 06
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders of Cryoport, Inc. ( NASDAQ:CYRX ) will be pleased this week, given that the stock price is up 17% to...Analysis Article • Feb 22
Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Cryoport, Inc. ( NASDAQ:CYRX ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Dec 03
Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Cryoport, Inc. ( NASDAQ:CYRX ) is a stock worth...Analysis Article • Nov 06
Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 09
The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Those holding Cryoport, Inc. ( NASDAQ:CYRX ) shares would be relieved that the share price has rebounded 36% in the...Analysis Article • Jul 22
Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • Jun 25
Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch
Unfortunately for some shareholders, the Cryoport, Inc. ( NASDAQ:CYRX ) share price has dived 28% in the last thirty...Analysis Article • Apr 15
Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
It's not a stretch to say that Cryoport, Inc.'s ( NASDAQ:CYRX ) price-to-sales (or "P/S") ratio of 3.7x right now seems...Shareholder Returns
| CYRX | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 12.1% | 9.4% | 1.6% |
| 1Y | 190.6% | 17.1% | 28.2% |
Return vs Industry: CYRX exceeded the US Life Sciences industry which returned 17.1% over the past year.
Return vs Market: CYRX exceeded the US Market which returned 28.2% over the past year.
Price Volatility
| CYRX volatility | |
|---|---|
| CYRX Average Weekly Movement | 8.5% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CYRX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 688 | Jerry Shelton | www.cryoportinc.com |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network.
Cryoport, Inc. Fundamentals Summary
| CYRX fundamental statistics | |
|---|---|
| Market cap | US$790.81m |
| Earnings (TTM) | -US$44.66m |
| Revenue (TTM) | US$182.94m |
4.3x
P/S Ratio-17.7x
P/E RatioIs CYRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYRX income statement (TTM) | |
|---|---|
| Revenue | US$182.94m |
| Cost of Revenue | US$96.61m |
| Gross Profit | US$86.33m |
| Other Expenses | US$130.99m |
| Earnings | -US$44.66m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 47.19% |
| Net Profit Margin | -24.41% |
| Debt/Equity Ratio | 37.7% |
How did CYRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/01 17:10 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cryoport, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Yuan Zhi | B. Riley Securities, Inc. |